2023: Scale Expansion Period (Leveraging RCEP + Product Upgrading)
1. Strategic Cooperation Achievements
Signed a Customized Chiral Intermediate Agreement with Germany's Merck Group: Supplied enantiopure (R)-phenylglycinol and (S)-lactic acid derivatives for Merck's cardiovascular drug production, with an annual supply volume of 3,800 tons and a contract value of 28 million US dollars. The products feature enantiomeric excess (ee) ≥ 99.5% and impurity content 1%, becoming Merck's core alternative to Japanese suppliers for this product category.
Participated in Thailand's Pharmaceutical Park Project: Provided key intermediates (including piperazine derivatives and imidazole compounds) for Thailand's National Pharmaceutical Manufacturing Center, and exported green synthesis technology. The project has a contract value of 180 million US dollars with an annual supply volume of 1,800 tons, supporting Thailand's local production of anti-diabetic and anti-hypertensive drugs.
2. Export Scale Cases
Explosive Export Growth in the RCEP Region: Taking advantage of RCEP's tariff reduction on pharmaceutical products (average tariff reduction from 8% to 0.5%), exported benzene series intermediates, heterocyclic compounds and other products to Australia, New Zealand and 8 ASEAN countries, with an annual export volume of 18,000 tons and an export value of 320 million RMB, a year-on-year increase of 65%. Among them, export growth to Malaysia and the Philippines exceeded 75%.
Export of High-purity API Intermediates to South America: For the first time exported cefazolin sodium intermediates and amoxicillin side chains to Brazil and Argentina, with an annual export volume of 3,000 tons and an export value of 47 million RMB. It has become a preferred import substitution brand in South America's API production industry, with market share increasing from 0 to 6%.
3. Market Breakthrough Cases
Leading Quinolone Intermediates in Southeast Asia: Developed norfloxacin intermediates (1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazin-1-yl-3-quinolinecarboxylic acid) tailored to the region's anti-infective drug demand, capturing 20% of the market in Vietnam and Indonesia with annual sales of 98 million RMB, a year-on-year growth of 90%. Cooperation clients include Daiichi Sankyo Vietnam and Kalbe Farma Indonesia.
RCEP Cross-border Pharmaceutical Logistics Optimization: Launched a dedicated cold-chain logistics route via Guangxi-Beibu Gulf Port to Southeast Asia, transporting temperature-sensitive intermediates (such as peptide intermediates) with an annual shipment volume of 10,000 tons, a 105% increase compared with 2022. Logistics costs were reduced by 18% and on-time delivery rate reached 99%.
Comprehensive Warehouse Solutions
With a broad level of expertise, Crown can serve as the single point of contact for your warehouse project.
Warehouse Design Services
Expert space-planning consultation for your specific needs
Racking & Storage Solutions
A broad selection of products for a customized storage system
Warehouse Products
All the products you need to complete your warehouse set up
Contact Us
Contact Us Let's TalkYour Any Query
Subscribe For Newsletter!
Your Email...
